| Nov 5 |
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
|
| Oct 31 |
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
|
| Oct 30 |
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for
|
| Oct 30 |
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
|
| Oct 29 |
Exelixis (EXEL) Q3 Earnings and Revenues Beat Estimates
|
| Oct 29 |
Arcus Biosciences: Advancing On Several Fronts
|
| Oct 24 |
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
|
| Oct 22 |
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
|
| Oct 21 |
Arcus started at neutral by H.C. Wainwright, upcoming data cited
|
| Oct 9 |
Arcus Biosciences Inc (RCUS) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid ...
|
